-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Bluejay Diagnostics (NASDAQ:BJDX) Trading 15.7% Higher
Bluejay Diagnostics (NASDAQ:BJDX) Trading 15.7% Higher
Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) shares traded up 15.7% on Thursday . The stock traded as high as $0.48 and last traded at $0.45. 9,936 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 507,309 shares. The stock had previously closed at $0.39.
Bluejay Diagnostics Price Performance
The stock has a market capitalization of $9.07 million and a PE ratio of -1.02. The business's fifty day moving average price is $0.68 and its 200-day moving average price is $0.92.
Get Bluejay Diagnostics alerts:Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, analysts expect that Bluejay Diagnostics, Inc. will post -0.29 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new stake in shares of Bluejay Diagnostics during the second quarter valued at approximately $54,000. Virtu Financial LLC purchased a new position in Bluejay Diagnostics during the second quarter valued at $45,000. Finally, Millennium Management LLC purchased a new position in Bluejay Diagnostics during the second quarter valued at $27,000. 0.94% of the stock is currently owned by institutional investors.Bluejay Diagnostics Company Profile
(Get Rating)
Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
Recommended Stories
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) shares traded up 15.7% on Thursday . The stock traded as high as $0.48 and last traded at $0.45. 9,936 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 507,309 shares. The stock had previously closed at $0.39.
BlueJay诊断公司(纳斯达克代码：BJDX-GET Rating)股价周四上涨15.7%。该股一度涨至0.48美元，最后报0.45美元。午盘有9,936股易手，较507,309股的平均成交量下降98%。该股此前收盘价为0.39美元。
Bluejay Diagnostics Price Performance
BlueJay诊断公司性价比
The stock has a market capitalization of $9.07 million and a PE ratio of -1.02. The business's fifty day moving average price is $0.68 and its 200-day moving average price is $0.92.
该股市值为907万美元，市盈率为-1.02。该业务的50日移动均线价格为0.68美元，200日移动均线价格为0.92美元。
Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, analysts expect that Bluejay Diagnostics, Inc. will post -0.29 earnings per share for the current fiscal year.
BlueJay Diagnostics(纳斯达克代码：BJDX-GET Rating)上一次公布季度收益数据是在11月9日星期三。该公司公布了本季度每股收益(0.14美元)，低于普遍预期的(0.08美元)和(0.06美元)。分析师平均预计Bluejay Diagnostics，Inc.本财年每股收益将为0.29美元。
Institutional Inflows and Outflows
机构资金流入和流出
Bluejay Diagnostics Company Profile
BlueJay诊断公司简介
(Get Rating)
(获取评级)
Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
BlueJay诊断公司是一家诊断公司，在美国开发和销售用于分诊、诊断和监测疾病进展的患者产品。它正在开发一个技术平台，包括使用非接触式离心力协调血液处理、生物标记物分离和免疫分析准备的SYMPHONY荧光免疫分析仪；以及包括试剂和组件的SYMPHONY卡片库。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 免费获取StockNews.com关于Bluejay诊断的研究报告(BJDX)
- 你买下Palantir的决定可能只是个时间问题
- 卡特彼勒和迪尔准备在2023年重整旗鼓吗？
- 马伦汽车公司在i-Go登陆欧洲之际受到震动
- 2023年，太阳会照耀这3只大盘太阳能股吗？
- Lucid Motors面临的现实可能会给看涨的看法蒙上阴影
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Bluejay诊断日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收Bluejay Diagnostics和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧